SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to widespread user outages linked to an AWS issue, sparking frustration and concerns about reliability as users were unable to access accounts or trade. Despite the disruption, the stock price has shown surprising resilience, leading to discussions on market dynamics and potential short squeezes. Community members are debating the platform's dependence on a single server and comparing it to competitors, while some speculate about manipulation.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology ($GSIT) is trending due to news of a Cornell-led paper validating its Compute-In-Memory Gemini-I APU, showing comparable throughput to NVIDIA GPUs with significantly lower energy consumption. The stock is seeing increased interest as community members discuss its potential to compete with major players in the AI chip market, with some speculating about potential buyout offers. Community members are also discussing short squeezes.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle $ORCL is trending as analysts attend Oracle's analyst day, where executives outlined impressive targets for fiscal year 2030, including revenue and EPS well ahead of consensus. The community is actively discussing whether these targets are achievable, especially given concerns around AI infrastructure spending and profitability, while some are pointing towards a potential pullback.

Aventus Network

Aventus Network ($AVT) is trending as the community discusses its potential, particularly highlighting its integration with Polkadot for interoperability. Recent news includes the founder's feature in Forbes discussing the future of agentic AI and its implications for blockchain. Some investors are noting the low market cap relative to its technology and partnerships.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune ($REPL) is trending due to news of the FDA accepting the resubmission of its Biologics License Application for RP1, a melanoma treatment, leading to significant price movement and trading volume. Community discussions revolve around updated price targets, the potential for a short squeeze, and collaborations with major pharmaceutical companies. However, some traders express caution, citing the long PDUFA timeline and potential for a pump and dump.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Recent news regarding the company's CEO taking a board seat at TLPH is sparking community interest, especially given CRMD's strategic investment in TLPH. Some investors speculate about a potential acquisition, while others are focused on upcoming clinical data for TLPH's Niyad and its potential impact on CRMD's growth. Bullish sentiment seems to be driven by institutional buying and anticipation of upcoming earnings and guidance.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as the company explores rare earth production at its U.S. mining sites, potentially pivoting from steel to strategic minerals. Community members are weighing in on the CEO's vision, buyout possibilities, and the potential impact of this move on debt reduction and shareholder value. Some traders express concerns about the CEO's past performance and the sustainability of the recent surge.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem ($VSTM) is trending as discussions revolve around positive clinical data for their KRAS G12D inhibitor, offset by concerns about management spending and potential dilution; the community is weighing the promising ORR data against alternative treatments and the company's history, with some anticipating a potential breakout or buyout, while others express frustration with management and short selling.

PIMCO Dynamic Income Fund is a non-diversified, closed-end management investment company. Its seeks current income as a primary objective and capital appreciation as a secondary objective. The company was founded on January 19, 2011 and is headquartered in New York, NY.

PIMCO Dynamic Income Fund

PDI is experiencing volatility, driven by a recent downgrade and discussions around its premium to NAV and dividend coverage amid higher interest rates, sparking community debate on whether to buy the dip or brace for further declines. Community members are actively debating whether this dip represents a buying opportunity or signals deeper problems within the fund, with some citing attractive monthly payouts and high yield. The fund's reliance on leverage and high-yield credit in a challenging rate environment adds to the uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at...

Forte Biosciences to Host RandD Day December 3, 2024

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will host an R&D Day...

The market’s resilience came under test on Wednesday as apprehensions ahead of earnings from artificial intelligence stalwart Nvidia Corp. (<a class="mention" data-mention="$NVDA" data-symbol-id="NVDA" href="https://stocktwits.com/symbol/NVDA" target="_blank">$NVDA</a>) generated some weakness early in the session.Nvidia stock was last seen trading down more than 1%, giving back some of the nearly 5% gain it made on Wednesday.As traders look ahead to the company’s market-moving&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ai-stalwart-nvidia-to-report-q3-2025-results-wednesday/cJ4UNCxRQC">earnings report,</a> due after the market close, here is a compilation of the most bullish stocks on Stocktwits:Forte Biosciences, In. (<a class="mention" data-mention="$FBRX" data-symbol-id="FBRX" href="https://stocktwits.com/symbol/FBRX" target="_blank">$FBRX</a>)&nbsp;Forte Biosciences shares were last seen rallying over 170% as the nano-cap autoimmune disorders-focused clinical-stage biopharma said its equity financing to support the continuing clinical advancement of its lead candidate FB102 was oversubscribed. “ As a result of the financing, Forte is well capitalized to continue advancing FB102 across autoimmune indications,” it added.Quantum-Si Inc. (<a class="mention" data-mention="$QSI" data-symbol-id="QSI" href="https://stocktwits.com/symbol/QSI" target="_blank">$QSI</a>):Shares of Quantum-Si, a medical-device company that develops a single-molecule detection platform to enable next-gen protein sequencing (NGPS), more than doubled on Wednesday on volumes that are notably above their 3-month average.The upside came after the company made a slew of announcements. Quantum-Si said Avantor, Inc. (<a class="mention" data-mention="$AVTR" data-symbol-id="AVTR" href="https://stocktwits.com/symbol/AVTR" target="_blank">$AVTR</a>) will distribute its NGPS portfolio, providing researchers across the U.S. and Canada access to the portfolio.In a separate release, Quantum-Si announced a collaboration with Nvidia to develop its next proteomics platform called Proteus and advance its core technologies of amino acid binders and amino peptidases using Nvidia AI and accelerated computing.&nbsp;Quantum-Si also announced an expanded partnership with SkyWater Technology, Inc. (<a class="mention" data-mention="$SKYT" data-symbol-id="SKYT" href="https://stocktwits.com/symbol/SKYT" target="_blank">$SKYT</a>) for developing Proetus and a separate deal with its contract manufacturing partner Planet Innovation for the same.&nbsp;Silexion Therapeutics Corp. (<a class="mention" data-mention="$SLXN" data-symbol-id="SLXN" href="https://stocktwits.com/symbol/SLXN" target="_blank">$SLXN</a>)Silexion, a clinical-stage biotech developing RNA interference therapies for certain types of cancers, disclosed in a filing on Tuesday that at the reconvened extraordinary general meeting, its shareholders approved the board recommendation for a reverse split of the shares in the ratio 1-for-9.&nbsp;The penny stock climbed 33% on Wednesday on above-average volume.Duos Technologies Group, Inc. (<a class="mention" data-mention="$DUOT" data-symbol-id="DUOT" href="https://stocktwits.com/symbol/DUOT" target="_blank">$DUOT</a>)Shares of Jacksonville, Florida-based Duos Tech, a software services provider, climbed over 17% after the company announced the signing of a $42 million worth of asset management agreement with Fortress Investment Group to deploy and operate a fleet of mobile gas turbines and balance-of-plant inventory that has a combined generation capacity of 850 megawatts.ZIM Integrated Shipping Services Ltd. (<a class="mention" data-mention="$ZIM" data-symbol-id="ZIM" href="https://stocktwits.com/symbol/ZIM" target="_blank">$ZIM</a>)Cargo shipping firm ZIM Integrated reported <a href="https://stocktwits.com/news-articles/markets/equity/zim-integrated-shipping-stock-rises-premarket-after-strong-q3-earnings/cJ46SQoRXc">upbeat third-quarter earnings</a> and raised its full-year guidance, sending its shares higher by over 7%. Retail hoped for large buyers increasing their exposure to the stock, sending it to the $31-$32 area by the close.<stembedurl>https://stocktwits.com/View2021/message/593365202</stembedurl>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-q3-2025-earnings-imminent/cJ46Z2LRXE">Nvidia Stock Slips Ahead Of Earnings: Gene Munster Explains Why Blackwell Chip Demand Commentary Is Important For Investors</a>

US Stocks dipped ahead of Nvidia earnings but a few sent retailers into a tizzy. 

5 Stocks Retail Investors Are Most Bullish On At Mid-Day

Retailers went overboard about a couple of biotech stocks and a MedTech name, among others on Wednesday.

Equity

Forte Biosciences Inc. (<a class="mention" data-mention="$FBRX" data-symbol-id="FBRX" href="https://stocktwits.com/symbol/FBRX" target="_blank">$FBRX</a>) saw its stock skyrocket by more than 150% on Wednesday afternoon, becoming the top gainer across U.S. markets.&nbsp;Trading volume surged to 19.2 million shares — approximately 1,800 times its daily average — as the stock hit levels last seen over six months ago.&nbsp;FBRX also ranked among the top 10 trending symbols on Stocktwits, with retail sentiment reaching a year’s high.The surge followed Forte’s announcement of an oversubscribed $53 million equity financing, led by high-profile institutional investors including OrbiMed, Janus Henderson Investors, and Tybourne Capital Management.&nbsp;The funds will support clinical development of FB102, Forte’s proprietary anti-CD122 monoclonal antibody targeting autoimmune and autoimmune-related diseases.“This financing by high quality institutional investors is transformative for Forte and highlights the meaningful potential for FB102,” said Forte CEO Paul Wagner.&nbsp;He reiterated that the company’s celiac disease trial is underway, with topline results expected by the second quarter of next year.&nbsp;Forte also plans to expand FB102 into additional indications over the next year, setting up 2025 as a milestone-heavy period for the biopharma company.The company said it will host an R&amp;D Day on Dec. 3 to provide further updates.&nbsp;FBRX remains down nearly 25% year-to-date.&nbsp;<figure class="image"><a href="https://stocktwits.com/symbol/FBRX"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/FBRX_sentiment_and_message_volume_on_Nov_20_fab7daafb7.png" alt="FBRX sentiment and message volume on Nov 20.png" width="1318" height="318"></a><figcaption>FBRX sentiment and message volume on Nov 20 as of 12:00 pm ET | source: Stocktwits</figcaption></figure>Retail investors on Stocktwits were exuberant, driving sentiment to ‘extremely bullish’ (97/100), the highest score since September, and message volume (90/100) to a one-year peak.<stembedurl>https://stocktwits.com/Fanafjell/message/593358026</stembedurl>&nbsp;<stembedurl>https://stocktwits.com/scalp_scalpnyc/message/593340028</stembedurl>Forte last week reported a third-quarter adjusted loss of $4.54 per share, better than analysts’ expectations of a $7.12 loss, despite generating no revenue.&nbsp;The fresh financing positions the company to advance FB102, which it views as a potentially broad-application therapeutic for autoimmune disorders.For updates and corrections, email&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pdyn-rcat-stocks-rise-on-ai-drone-partnership-boost/cJ46NR6RX4">Palladyne, Red Cat Stocks Soar On Expanded AI Drone Collaboration And Key Defense Contract Win: Retail Optimism Grows</a>

Forte also plans to expand FB102 into additional indications over the next year

Forte Biosciences Stock More Than Doubles On Oversubscribed $53M Private Placement: Retail Goes Wild

The funds will support clinical development of FB102, Forte’s proprietary anti-CD122 monoclonal antibody targeting autoimmune and autoimmune-related diseases.

Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced an oversubscribed $53...

Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2024...

Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced second quarter 2024...

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity...

Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced first quarter 2024...

FY2024 EPS Estimates for Forte Biosciences, Inc. Increased by Analyst (NASDAQ:FBRX)

Forte Biosciences, Inc. (NASDAQ:FBRX  Free Report)  Investment analysts at Chardan Capital boosted their FY2024 EPS estimates for shares of Forte Biosciences in a research note issued...

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner in 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

FBRX
Forte Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest FBRX News

FBRXForte Biosciences Inc